BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create therapies that address the genetic roots of diseases, potentially leading to significant improvements in patient outcomes. With over 15 drug programs targeting 20 different genetic diseases, BridgeBio aims to reduce the time it takes to bring new treatments to market. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Viking Global Investors

Perceptive Advisors

Aisling Capital

AIG Investments

CORMORANT CAPITAL STRATEGIES LIMITED

American International Group

Sequoia

Hercules Capital

EcoR1 Capital

Deerfield

Cormorant Asset Management

Casdin Capital

Surveyor Capital

Enavate Sciences

Longwood Fund

Wellington Management

Omega Funds

Qatar Investment Authority

Biotechnology

BridgeBio

PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

PANTHERx Rare, a leader in rare disease product patient access and support services in the United States, also announced that it was selected by BridgeBio for the distribution of Attruby (acoramidis).

Orsini and PANTHERx Rare Selected by BridgeBio as Pharmacy Partners for ATTRUBY

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by BridgeBio for the distribution of Attruby™ (acoramidis), a high-affinity transthyretin (TTR) stabilizer for twice daily oral administration, approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).2,5. Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby was designed to mimic a naturally occurring "rescue mutation" of the TTR gene (T119M) that targets the root cause of ATTR-CM, destabilization of the native TTR tetramer. Through near-complete TTR stabilization, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes. "Panther is committed to providing tailored solutions for people living with rare and devastating conditions and we look forward to the partnership with BridgeBio and serving the needs of patients suffering from transthyretin amyloid cardiomyopathy," said Rob Snyder, Executive Chair, PANTHERx® Rare Pharmacy

Bridgebio Selects Pantherx® Rare Specialty Pharmacy For Distribution Of Attruby™ (Acoramidis)

Jennison Associates LLC invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO).

Jennison Associates LLC Invests $767,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage precision oncology company, has announced the appointment of Yong (Ben) Ben, MD, as Chief Medical and Development Officer.

BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Global Genes' Annual Week In Rare Event Heading To Kansas City

Pictured (from left): Pfizer and Alnylam signs/Taylor Tieden for BioSpaceUnveiled late last month, topline results from a Phase III trial of Alnylam’s RNAi therapy Amvuttra in ATTR amyloidosis with cardiomyopathy are turning some heads. The treatment showed a statistically significant reduction in all-cause mortality and recurrent cardiovascular events.“I expected this readout to be positive, but this was extremely positive,” said Kostas Biliouris, director and equity research analyst at Bank of Montreal Capital Markets. “I think the results reflect the best-case scenario.”The initial results appear promising, but a clearer picture will emerge when the full data come out later this summer. Further details of the HELIOS-B study will be presented as an abstract at the European Society of Cardiology’s congress in London, taking place Aug. 30 to Sept. 2.Paul Matteis, head of the therapeutics research team at Stifel, told BioSpace that not having those details is one of the biggest open questions at the moment

Alnylam Could Challenge Pfizer In Attr-Cm But Experts Want Full Data

PALO ALTO, Calif., July  05, 2024  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. BBIO ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on July 2, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 25 new employees in restricted stock units for an aggregate of 123,070 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the "Plan").The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases

Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Norges Bank makes new $46.84 million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO).

Norges Bank Makes New $46.84 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Some of the deadliest cancer mutations occur in a gene called KRAS. Drugs that target this gene to stop cancer cells from growing further are known as KRAS inhibitors, which have been regarded as a step forward in cancer research.These drugs seem to hold clinical promise as, only recently, a spinout of California-based BridgeBio launched with $200 million to solely focus on the development of KRAS inhibitors. A phase 1 study for bbo-8520 is currently enrolling participants. Drugging the undruggableOver the last three decades, KRAS mutations were considered undruggable. The term undruggable refers to target sites (for a specific disease) lacking the ability to interact with other molecules including drugs. This posed a serious challenge when designing drugs to bind to KRAS mutations.Dr. Emiliano Calvo, director of Clinical Research at START Madrid-Centro Integral Oncológico Clara Campal (CIOCC) hospital in Spain, explained that KRAS proteins in particular, had a smooth surface with only few pockets for a drug to bind effectively

BridgeBio

Develops medicines for genetic diseases

BridgeBio

Develops medicines for genetic diseases

About

Simplify's Take

What believers are saying

What critics are saying

What makes BridgeBio unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

BridgeBio is Hiring for 0 Jobs on Simplify!